The proposed mechanism for DRB’s alleviation of CRC development includes inhibition of inflammatory marker expression via the NF-κB signaling pathway and blocking of the activation of β-catenin, cyclin D1, and c-Myc through the Wnt/β-catenin signaling pathway in the colon. Here, CCND1 is linked to colorectal carcinoma.